Story
Indian Pharma Stocks Decline After Trump Outlines Future Tariffs on Generic Drugs
Indian pharmaceutical stocks retreated on Wednesday following a proposal by U.S. President Donald Trump to impose significant future tariffs on imported generic drugs. The plan threatens the profitability of Indian drugmakers, for whom the United States is a critical export market.
Market Reaction
The Nifty Pharma Index, a key benchmark for the sector in India, fell by 1% in response to the news. The decline was widespread among major manufacturers that have significant exposure to the U.S. market.
Key stock movements included:
- Aurobindo Pharma Ltd., Cipla Ltd., Lupin Ltd., and Glenmark Pharmaceuticals Ltd. each fell between 2% and 3%.
- Sun Pharmaceutical Industries Ltd., India's largest drugmaker, saw its shares decline by 1.2%.
- Dr Reddy’s Laboratories Ltd. and Zydus Lifesciences Ltd. dropped by 1.4% and 2.4%, respectively.
Details of the Tariff Proposal
AdIn a statement on Tuesday evening, President Trump outlined a phased approach to the new tariffs. According to the plan, imported generic drugs will remain exempt from duties until August 2028.
Following that date, a 100% tariff would be imposed on these imports. The levy is scheduled to increase further to 200% by 2029. The stated objective of the policy is to encourage the domestic manufacturing of generic drugs and other pharmaceuticals within the United States.
Context and Implications
The proposed tariffs represent a significant potential challenge for Indian pharmaceutical companies, which are major suppliers of generic medicines to the U.S. market. Higher import duties would directly compress the profit margins of these exporters.
The policy aligns with previous efforts by the Trump administration aimed at reducing U.S. dependence on foreign manufacturing and strengthening domestic supply chains. The long lead time before the tariffs take effect gives companies several years to adapt, but the announcement introduces substantial long-term uncertainty for the sector.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.
Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.
Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.
DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.